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Abstract
Mammalian gene regulation is dependent on tissue-specific enhancers that can act across large
distances to influence transcriptional activity1-3. Mapping experiments have identified hundreds of
thousands of putative enhancers whose functionality is supported by cell type–specific chromatin
signatures and striking enrichments for disease-associated sequence variants4-11. However, these
studies did not address the in vivo functions of the putative elements or their chromatin states and
could not determine which genes, if any, a given enhancer regulates. Here we present a strategy to
investigate endogenous regulatory elements by selectively altering their chromatin state using
programmable reagents. Transcription activator–like (TAL) effector repeat domains fused to the
LSD1 histone demethylase efficiently remove enhancer-associated chromatin modifications from
target loci, without affecting control regions. We find that inactivation of enhancer chromatin by
these fusion proteins frequently causes down-regulation of proximal genes, revealing enhancer
target genes. Our study demonstrates the potential of ‘epigenome editing’ tools to characterize an
important class of functional genomic elements.
Here we sought to develop a strategy for testing the functions of genomic elements and
associated chromatin states in their endogenous context. We focused on active enhancers,
which are marked by histone H3 K4 mono- and di-methylation (H3K4me1 and H3K4me2)
and K27 acetylation (H3K27ac)4,6,9,12,13. We hypothesized that a given enhancer could be
inactivated by removal of these chromatin marks. To test this hypothesis, we engineered
monomeric fusions between TAL effector repeat arrays and the lysine-specific demethylase
1 (LSD1)14. TAL effector repeats are modular DNA-binding domains that can be designed
to bind essentially any genomic sequence of interest15,16. LSD1 catalyzes the removal of H3
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tK4 and H3 K9 methylation1-3,14. Although prior studies have used TAL effector nucleases
to edit specific genomic regions to disrupt coding sequences4-11,17,18, we reasoned that TAL
effector-LSD1 fusions could provide a more versatile means for modulating the activity of
noncoding elements and evaluating the significance of their chromatin states.
We initially focused on a candidate enhancer in the stem cell leukemia (SCL) locus that is
enriched for H3K4me2 and H3K27ac in K562 erythroleukemia cells4,6,9,12,13,19. SCL
encodes a developmental transcription factor with critical functions in hematopoiesis that is
expressed in K562 cells. We designed a TAL effector array to bind an 18 base sequence in a
segment of this enhancer predicted to be nucleosome-free based on DNase hypersensitivity
(Fig. 1A, see Methods). As the binding specificity of monomeric TAL effectors has yet to
be thoroughly characterized, we first created an expression construct encoding this TAL
effector array fused to a 3X FLAG epitope. We transfected this construct into K562 cells,
confirmed expression by Western blot, and mapped genome-wide binding by chromatin
immunoprecipitation and sequencing (ChIP-seq). We found that the top ranked binding site
corresponds precisely to the target sequence within the SCL locus (Figure 1B,
Supplementary Fig. 1). We did not identify any other ChIP-seq peaks that were reproducibly
detected in the two biological replicates. We also scanned the genome for sequence motifs
with one or two mismatches from the TAL effector recognition motif, but did not detect any
significant ChIP-seq enrichments at these sites either (Supplementary Fig. 1). These data
support the specificity of TAL effector binding and are consistent with prior demonstrations
of TAL effector activator domain fusions that selectively induce target genes14,18,20.
To modulate chromatin state at the SCL enhancer, we combined the corresponding TAL
effector with the LSD1 demethylase. We transfected K562 cells with a construct encoding
this TAL effector-LSD1 (TALE-LSD1) fusion or a control mCherry vector, cultured the
cells for three days and measured histone modification levels by ChIP-qPCR. We found that
the fusion reduced H3K4me2 signals at the target locus by ~3-fold relative to control, but
had no effect at several non-target control enhancers (Fig. 1C, Supplementary Fig. 2). In
addition to its enzymatic activity, LSD1 physically interacts with other chromatin modifying
enzymes, including histone deacetylases21. We therefore also tested for changes in
H3K27ac, another characteristic enhancer mark. We found that the fusion reduced H3K27ac
levels by >4-fold, suggesting that LSD1 recruitment leads to generalized chromatin
inactivation at the target enhancer.
To eliminate the possibility that the chromatin changes reflect displacement of other
transcription factors by the TAL effector, we tested a construct encoding the TAL effector
without LSD1. We also examined a TALE-LSD1 fusion with a scrambled target sequence
not present in the human genome to control for non-specific effects of LSD1
overexpression. Neither construct altered H3K4me2 or H3K27ac levels at the SCL locus
(Fig. 1C, Supplementary Fig. 3). Lastly, to evaluate the specificity of the fusion
comprehensively, we used ChIP-seq to map H3K4me2 and H3K27ac genome-wide in
TALE-LSD1 and control transfected K562 cells. These data confirmed loss of H3K4me2
and H3K27ac across a 2 kb region surrounding the target sequence within the SCL locus
(Fig. 1D).
These results indicate that directed LSD1 recruitment results in locus-specific reduction of
H3K4me2 and H3K27ac. The generalized effect on chromatin state may be a direct
consequence of H3K4 demethylation or, alternatively, may depend on partner proteins that
associate with LSD115,16,22,23. Regardless, prior studies indicate that sequence elements
enriched for H3K4me2 and H3K27ac exhibit enhancer activity in corresponding cell types,
whereas elements lacking these marks are rarely active4,6,12. Hence, our results suggest that
this TALE-LSD1 fusion efficiently and selectively inactivates its target enhancer.
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tWe therefore expanded our study to investigate a larger set of candidate enhancers with
active chromatin in K562 cells. These include nine elements in developmental loci, sixteen
additional highly cell type-specific elements, and fifteen intergenic elements. We designed
and produced TALE repeat arrays for sequences in these 40 enhancers using the Fast
Ligation-based Automatable Solid-phase High-throughput (FLASH) assembly
method24(Supplementary Table 1). We then cloned LSD1 fusion constructs for each TALE
and transfected them individually into K562 cells, alongside mCherry control plasmid
transfected separately into cells. At three days post transfection, we measured H3K4me2 and
H3K27ac by ChIP-qPCR using two primer sets per target enhancer. We found that 26 of the
40 TALE-LSD1 constructs (65%) substantially reduced levels of these modifications at their
target loci, relative to control transfected cells (Fig. 2; see Methods). An additional 8
constructs caused more modest reductions at their targets, suggesting that the strategy can be
effective at most enhancers (Fig. 2). ChIP-qPCR measurements of H3K4me1 and H3K4me3
confirm that the reagents also reduce these alternative H3K4 methylation states
(Supplementary Fig. 4). The induced changes were specific to the target loci, as analogous
measurements at non-target enhancers did not reveal substantial changes (Supplementary
Fig. 5). Furthermore, genome-wide ChIP-seq analysis of two TALE-LSD1 fusions that were
positive by ChIP-qPCR confirmed the robustness and specificity with which they reduce
chromatin signals at target loci (Supplementary Fig. 6).
We next considered whether reduced chromatin activity at specific enhancers affects the
transcriptional output of nearby genes. We initially focused on 9 TALE-LSD1 fusions that
robustly alter chromatin state (Fig. 2), and systematically screened for regulated genes using
a modified RNA-seq procedure termed 3′ Digital Gene Expression (3′DGE). By only
sequencing the 3′ ends of mRNAs, this procedure enables quantitative analysis of transcript
levels at modest sequencing depths25 (Garber M., manuscript in review). We transfected the
9 TALE-LSD1 constructs individually into K562 cells, alongside with control mCherry
plasmids and measured mRNA levels in biological replicate. We normalized each 3′DGE
dataset based on a negative binomial distribution and excluded any libraries that did not
satisfy quality controls (see Methods)26. We then examined whether any of the TALE-
LSD1 reagents substantially altered the expression of genes in the vicinity of its target
enhancer. Four of the nine tested fusions (44%) caused a nearby gene to be down-regulated
by at least 1.5-fold, with both biological replicates for the tested fusion exhibiting larger
expression change than any of the other effectors or controls (see Methods, Fig. 3A,
Supplementary Fig. 7).
The significance of these transcriptional changes is supported by a simulated analysis of a
random sampling of 1000 genomic locations that did not yield any false-positives in which
an adjacent gene scored as regulated (FDR<0.1%). The expression changes were also
confirmed by quantitative RT-PCR (Supplementary Fig. 8). Two of the enhancers that
significantly regulated genes are intergenic, wheras a third coincides with the 3′ end of a
gene, but affects the activity of the next downstream gene. The fourth scoring enhancer
resides in the first intron of ZFPM2. We confirmed that ZFPM2 down-regulation requires
LSD1 recruitment, as a TALE lacking the demethylase did not affect its expression
(Supplementary Fig. 8). We cannot distinguish whether the other five putative enhancers
have weak transcriptional effects below our detection threshold or, alternatively, do not
regulate any genes in K562 cells. Regardless, our results indicate that TALE-LSD1 fusions
can alter enhancer activity in a targeted, loss-of-function manner, and thereby enable
identification and modulation of their target genes.
The high prevalence of putative enhancers in the genome suggests that many act redundantly
or function only in specific contexts, which could explain our inability to assign target genes
to roughly half of the tested elements. To address the former, we examined three putative
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tenhancers within the developmental locus encoding ZFPM2 (Fig. 3B). In addition to the
TALE-LSD1 fusion targeted to the intronic enhancer described above (Fig. 3A, 3B;
enhancer +10), we designed and validated TALE-LSD1 fusions that reduced modification
levels at two additional intronic ZFPM2 enhancers (enhancers +16, +45) (Fig. 2, 3B). First,
we transfected each TALE-LSD1 fusion individually and tested their effects on ZFPM2
expression by qPCR. Whereas the fusion targeting the original +10 enhancer reduced
ZFPM2 expression by ~2-fold, the fusions targeting the +16 and +45 enhancers showed only
modest reductions of ~13% and ~22%, respectively, that did not reach statistical
significance (Fig. 3C). To determine if these enhancers act additively or synergistically, we
transfected the fusions in pairwise combinations. Although targeting pairs of enhancers
tended to reduce gene expression more than hitting a single enhancer, the cumulative effects
were substantially less than the sum of the two individual effects. This suggests that the
multiple enhancers in this locus function redundantly to maintain ZFPM2 expression in
K562 cells. These results indicate the potential of programmable TALE-LSD1 fusions to
shed light on complex regulatory interactions among multiple enhancers and genes in a
locus.
In conclusion, our study presents epigenome editing tools to modulate the activity of a
poorly characterized class of functional genomic elements in their native contexts. The
approach should also be useful for directing alterations of other epigenomic features,
including repressive chromatin states and potentially with temporal control27. We
demonstrate that programmable TALE-LSD1 fusions can be used to modulate the chromatin
state and regulatory activity of individual enhancers with high specificity. These reagents
should be generally useful for evaluating candidate enhancers identified in genomic
mapping studies with higher throughput than direct genetic manipulations, particularly when
combined with high-throughput methods for engineered TAL effector-based proteins24.
Moreover, the approach may allow researchers to modulate developmental or disease-
associated genes in specific contexts by inactivating their tissue-specific enhancers, and thus
ultimately yield new therapeutic strategies.
Online Methods
Construction of TAL effector fusions
The open reading frame for LSD1 was amplified from a cDNA library from K562 cells
using the following primers (F:gttcaagatctttatctgggaagaaggcgg,
R:gaccttaattaaatgggcctcttcccttagaa). The PCR product was cloned into a TAL effector
compatible expression vector28 using PacI and BamHI/BglII such that LSD1 is fused to the
C-terminal end of the TAL effector. TAL effector repeat array monomers were designed and
assembled using FLASH as described24. These assembled DNA fragments were cloned into
the expression vector using BsmBI sites and verified by restriction enzyme digestion and
sequencing. The mCherry control vector was created by incorporating an mCherry open
reading frame in place of the TAL effector array using NotI and PacI. Control TAL effector
vectors lacking LSD1 were constructed using BamHI and PacI to remove LSD1, followed
by blunt end ligation. The 3X Flag Tagged TAL effector vector was created by designing a
gBlock (IDT) encoding a 29 amino acid Glycine:Serine linker followed by the 3X Flag
sequence and cloning into the BamHI and PacI sites at the C-terminal end of the TAL
effector repeat. Plasmids for construction of LSD1 and 3X Flag fusions will be available
from Addgene.
Cell culture and transfection
The human erythroleukemia cell line, K562 (ATCC, CLL-243), was cultured in RPMI with
10% FBS, 1% Pen/Strep (Life Technologies). For transfections, 5 × 10^6 cells per
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ttransfection were washed once with PBS. Cells were then transfected with 20 ug of TAL
effector plasmid DNA or control mCherry plasmid by nucleofection with Lonza Kit V, as
described by the manufacturer (Program T-016). Cells were immediately resuspended in
K562 media at a density of 0.25 × 10^6 cells/ml. Cells were harvested at 72 hours for ChIP
or RNA extraction. For ZFPM2 gene expression analysis, we standardized the total amount
of DNA per transfection by co-transfecting either 10ug of a single TALE-LSD1 plasmid
plus 10 ug of a scrambled TALE-LSD1 plasmid, or 10ug each of two TALE-LSD1
plasmids. Transfection efficiency, determined by flow cytometry analysis of mCherry
control transfected cells, ranged from 89-94% across multiple biological replicates.
Flag tagged ChIP
TALE-3X Flag transfected K562 cells were crosslinked with 0.5% formaldehyde for 5
minutes at room temperature. Nuclei were isolated and lysed as described29. After
sonication, solubilized chromatin was incubated with protein G Dynabeads (Invitrogen) and
0.5 ug anti-FLAG M2 antibody (Sigma) at 4C overnight. Samples were washed with TBS-T,
low salt (150 mM NaCl, 2mM Tris-HCl, 1% Triton-X), LiCl (250mM LiCl, 1mM Tris-HCl,
1% Triton-X), and high salt (750mM NaCl, 2 mM Tris-HCl, 1% Triton-X) buffers at room
temperature. Enriched chromatin was eluted (1% SDS, 5mM DTT) at 65 C for 20 minutes,
purified and used directly for Illumina library prep. A control library was made from input
DNA diluted to 50 picograms. Reads were aligned using Bowtie, and peak analysis was
done using MACS with input controls, and masking genomic regions repetitive in Hg19 or
K56230.
Native ChIP
Quantitative measurements of histone modification levels were preformed in parallel using
native ChIP. 0.01 U of MNase (ThermoScientific) was added to 1 ml lysis buffer (50mM
Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.1% sodium deoxycholate, 1mM CaCl2) with
EDTA free proteinase inhibitor. For each transfected sample, 260 ul of MNase:Lysis buffer
was added and incubated for 15 minutes at 25 C, and 20 minutes at 37C. MNase was
inactivated by adding 20 mM EGTA. The lysed sample was split into 96 well plate format
for ChIP with H3K4me2 (abcam ab32356), H3K27ac (Active Motif 39133), H3K4me3
(Abcam ab8580), or H3K4me1 (Abcam ab8895). Antibody binding, bead washing, DNA
elution and sample clean-up were performed as described31. ChIP DNA was analyzed by
real-time PCR using FastStart Universal SYBR Green Master (Applied Biosystems), and
enrichment ratios were calculated relative to equal amount of input DNA. Enrichment was
normalized across ChIP samples to two standard off-target control enhancers
(Supplementary Table 2), and fold-ratios were calculated relative to mCherry plasmid
transfected cells assayed in parallel. Each TAL effector ChIP experiment was performed in a
minimum of 3 biological replicates. TAL effector-LSD1 reagents were scored based on the
fold-changes of H3K4me2 and H3K27ac for two primers flanking the target sequence. A
given reagent was scored ‘positive’ if it induced a 2-fold or greater reduction in modification
signal for at least 2 of these 4 values, with a p-value<0.05 using a one-tailed t-test. For
ChIP-seq maps, 5 ng of ChIP DNA was used for library preparation as described31.
Gene expression analysis
Genome-wide RNA expression analysis was performed using 3′DGE RNA-seq. Total RNA
from 1 million TALE-LSD1 transfected or control (K562 alone or mCherry plasmid
transfected) cells in biological replicate using RNeasy Mini kit (Qiagen). 2 ug of total RNA
was fragmented and the 3′ ends of polyA mRNAs were isolated using Dynabeads
(Invitrogen), and used to generate Illumina sequencing libraries, as described25. To precisely
quantify the gene expression, we used a 3′ DGE analysis pipeline (Garber M., in
preparation, http://garberlab.umassmed.edu/software/esat/). The pipeline estimates gene
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texpression based on the maximum number of reads in any 500 basepair window within 10
kb of the annotated 3′ gene end. This approach compensates for the fact that annotated ends
for some genes are imprecise and may be cell type dependent and yields accurate
quantifications. We then normalized the gene expression levels, scaling samples by the
median gene inter-sample variation, as described in26. This approach controls for differences
in sequencing depth between libraries and in the overall transcript abundance distribution.
We excluded libraries with extreme normalization coefficients below 0.7 or above 1.5. To
identify candidate regulated genes, we examined the three closest upstream and three closest
downstream genes. We scored a gene as regulated if (i) it was detected in control K562 cells
with a normalized RNA-seq value >10, i.e. the top 50th percentile of expression; (ii) its
mean expression value was at least 1.5-fold lower in the corresponding on-target TALE-
LSD1 libraries compared to all other libraries, p < 0.05 calculated using DESeq26 and (iii)
its normalized 3′DGE values in the on-target TALE-LSD1 libraries were the two lowest
over all 22 datasets. To simulate the 1000 random binding sites, we sample genomic
positions uniformly at random and use rejection sampling to ensure that the random set has a
similar distribution relative to genomic annotations (intergenic, promoter, gene body, UTR)
to the actual TAL effector binding sites. We then used significance testing criteria identical
to that applied to the actual TAL effector experiments.
For RT-PCR based expression analysis, total RNA was extracted and reverse transcribed
into cDNA using Superscript III First-Strand Synthesis system for RT-PCR (Invitrogen).
Quantitative PCR was performed with FastStart Universal SYBR Green Master (Invitrogen)
with primer sequences listed in Table S2 on an ABI 7500 machine. Gene expression values
are presented as log2 Ct ratios relative to 2 housekeeping control genes (TBP and SDHA),
and represents an average of four independent biological replicates each assayed in two
technical replicates.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Programmable TALE-LSD1 fusion modulates chromatin at an endogenous enhancer. (a)
Schematic depicts workflow for identification of nucleosome-free target sequence (black
stripe) within enhancer (blue peaks of histone modification) and design of corresponding
TAL effector fusion. TAL effector arrays comprising ~18 repeats (colored ovals) that each
bind a single DNA base are fused to the LSD1 histone H3K4 demethylase. Upon transient
transfection, we assayed for binding to the target site, induced chromatin changes and
altered gene expression. (b) ChIP-seq signal tracks show H3K4me2, H3K27ac and TALE
binding in K562 cells across a targeted enhancer in the SCL locus. Control tracks show anti-
FLAG ChIP-seq signals in mCherry transfected cells and input chromatin. The target
sequence of the TALE is indicated below. (c) ChIP-qPCR data show fold-change of
H3K4me2 and H3K27ac enrichment in cells transfected with constructs encoding TALE-
LSD1, the same TALE but lacking LSD1, or a ‘non-target’ TALE-LSD1 whose cognate
sequence is not present in the human genome. Data are presented as log2 ratios normalized
to mCherry plasmid transfected control (error bars represent ±s.e.m. n=4 biological
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treplicates). (d) ChIP-seq tracks show H3K4me2 and H3K27ac signals across the target SCL
locus for K562 cells transfected with TAL effector-LSD1 or control mCherry plasmid.
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TALE-LSD1 fusions targeting 40 candidate enhancers in K562 cells. The FLASH assembly
method was used to engineer 40 TALE-LSD1 fusions that recognize 17 – 20 base sequences
in nucleosome-free regions of candidate enhancers. These reagents were transfected into
K562 cells and evaluated by ChIP-qPCR. Bi-directional plot shows fold change of
H3K4me2 (green, left) and H3K27ac (blue, right) at the target locus for each of the 40
fusions, which are ordered by strength of effect and labeled by their target genomic site.
Most target sites were evaluated using two qPCR primer sets. Data are presented as log2
ratios normalized to mCherry plasmid transfected control (error bars represent ±s.e.m., n=3
biological replicates). The solid red lines define a 2-fold difference (log2 = −1). The dashed
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tred line demarcates constructs that induce a 2-fold reduction in histone modification levels
for two or more of the four values shown. Regulated genes for 9 tested fusions are shown at
right (see text and Figure 3). The data indicate that TALE-LSD1 reagents provide a general
means for modulating chromatin state at endogenous enhancers.
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TALE-LSD1 fusions to endogenous enhancers affect proximal gene expression. (a) Nine
TALE-LSD1 fusions that robustly alter chromatin state (see Figure 2) were evaluated for
their effects on gene expression by RNA-seq (see Methods). For each of the nine fusions, a
bar graph shows normalized gene expression values for the closest expressed upstream and
downstream genes. The red and pink bars indicate the gene expression value for two
biological replicates in cells transfected with the corresponding ‘on-target’ TALE-LSD1
construct, and the black bars indicate the mean expression in cells transfected with control
‘off-target’ TALE constructs (error bars for the “Control” represent s.e.m, n=20 non-target
libraries, see Methods, * indicates p <0.05 using an unpaired t-test). (b) ChIP-seq tracks
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tshow H3K4me2 and H3K27ac signals across the Zfpm2 locus. TAL effector-LSD1 fusions
were designed to target candidate enhancers (black bars) in the first intron. (c) Bar graph
shows relative ZFPM2 expression in K562 cells transfected with the indicated combinations
of TALE-LSD1 constructs. Error bars indicate ±s.e.m of 4 RT-qPCR measurements). The
data suggest that these enhancers act redundantly in K562 cells to maintain ZFPM2
expression.
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